Factors to consider when selecting initial therapy in CLL: patient features & preference

The two main options for initial treatment of chronic lymphocytic leukemia (CLL) are continuous BTK inhibitor therapy, or one-year time-limited therapy. Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, explains factors to consider when selecting initial therapy for patients with CLL, discussing which patient features should be considered and highlighting the role of patient preference. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.